Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Others

Bioregenx (BRGX) Share-based Compensation (2024 - 2025)

Bioregenx has reported Share-based Compensation over the past 2 years, most recently at -$254021.0 for Q4 2025.

For Q4 2025, Share-based Compensation fell 118.69% year-over-year to -$254021.0; the TTM value through Sep 2025 reached $1.6 million, up 8.14%, while the annual FY2024 figure was $2.9 million, 27.37% up from the prior year.
Share-based Compensation for Q4 2025 was -$254021.0 at Bioregenx, down from $254021.0 in the prior quarter.
Over five years, Share-based Compensation peaked at $1.7 million in Q1 2024 and troughed at -$331303.0 in Q3 2024.